Vertex Pharma (VRTX) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY26 Revenue Guidance

Vertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $4.73, $0.01 better than the analyst estimate of $4.72. Revenue for the quarter came in at $3.33 billion versus the consensus estimate of $3.22 billion.

GUIDANCE:

Vertex Pharma sees FY2026 revenue of $13.1-13.2 billion, versus the consensus of $13.05 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
• RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)